by James Smith | Dec 11, 2014
. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York...
by James Smith | Dec 9, 2014
. With contributions from David Brindley. Suppose you are a talented fisherman and an outstanding shoe-maker. You have abandoned your dreams of a career in the regenerative medicine industry because, in one day, you can catch 100 fish or make one complete pair of...
by Mark Curtis | Dec 4, 2014
. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably...
by Mark Curtis | Nov 20, 2014
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its...
by Sara M. Nolte | Sep 29, 2014
> It’s September again! That means new grad students in the lab, seminars and courses start again, committee meetings, grant deadlines, product shows, and… Journal Club. What is Journal Club – and why am I about to spend an entire post talking about it? Ideally, it...
Comments